National Institute of Neurology and Neurosurgery Manuel Velasco Suarez INNNMVS

Mexico City, Mexico

National Institute of Neurology and Neurosurgery Manuel Velasco Suarez INNNMVS

Mexico City, Mexico

Time filter

Source Type

PubMed | CINVESTAV, National Institute of Neurology and Neurosurgery Manuel Velasco Suarez INNNMVS, National Autonomous University of Mexico, National Institute Of Psychiatry Ramon Of La Fuente Muniz Inprfm and University of Alabama at Birmingham
Type: | Journal: Neuroscience | Year: 2016

A putative role of the brain-derived neurotrophic factor (BDNF) in epilepsy has emerged from in vitro and animal models, but few studies have analyzed human samples. We assessed the BDNF expression of transcripts with exons I (BDNFI), II (BDNFII), IV (BDNFIV) and VI (BDNFVI) and methylation levels of promoters 4 and 6 in the hippocampi of patients with pharmaco-resistant temporal lobe epilepsy (TLE) (n=24). Hippocampal sclerosis (HS) and pre-surgical pharmacological treatment were considered as clinical independent variables. A statistical significant increase for the BDNFVI (p<0.05) was observed in TLE patients compared to the autopsy control group (n=8). BDNFVI was also increased in anxiety/depression TLE (N=4) when compared to autopsies or to the remaining group of patients (p<0.05). In contrast, the use of the antiepileptic drug Topiramate (TPM) (N=3) was associated to a decrease in BDNFVI expression (p<0.05) when compared to the remaining group of patients. Methylation levels at the BDNF promoters 4 and 6 were similar between TLE and autopsies and in relation to the use of either Sertraline (SRT) or TPM. These results suggest an up-regulated expression of a specific BDNF transcript in patients with TLE, an effect that seems to be dependent on the use of specific drugs.

Loading National Institute of Neurology and Neurosurgery Manuel Velasco Suarez INNNMVS collaborators
Loading National Institute of Neurology and Neurosurgery Manuel Velasco Suarez INNNMVS collaborators